In this edition issue:
Personalised B-cell tailored dosing of ocrelizumab for MS
Cellular and humoral immunity to SARS-CoV-2 infection in MS patients on DMTs
Intrathecal IgM synthesis is associated with spinal cord manifestation and neuronal injury in early MS
Hormone therapy and disease activity in women with MS
No increase of sNfL in RRMS patients switching from standard to extended-interval dosing of natalizumab
Review and guidelines for anti-CD20 therapies in pregnancy and breastfeeding
Establishment of reference values for plasma NfL
DMTs for MS and association with survival
MS disease burden below the clinical threshold
Shift of MS onset towards older age
Please login below to download this issue (PDF)